Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

被引：9
|
作者：
Khozin, Sean
Walker, Mark S.
Jun, Monika
Chen, Li
Stepanski, Edward
Rubinstein, Wendy S.
Komatsoulis, George Anthony
Roberts, Jeremy
Zhi, Jizu
Miller, Robert S.
Fukushima, Ryan
Lau, Denise
Hyde, Brigham
机构：
[1] US FDA, Silver Spring, MD USA
[2] ACORN Res LLC, Memphis, TN USA
[3] Concerto HealthAI, Boston, MA USA
[4] Amer Soc Clin Oncol ASCO CancerLinQ, Alexandria, VA USA
[5] Tempus, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.110
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
110
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Ramucirumab (ram), immune checkpoint inhibitors (ICIs), and single-agent chemotherapy (chemo) usage in real-world advanced non-small cell lung cancer (aNSCLC) patients (pts) after rapid disease progression (RDP) on platinum (Pt).
    Batus, Marta
    Molife, Cliff
    Miksad, Rebecca A.
    Clarke, Jeffrey Melson
    Stefaniak, Victoria Jennifer
    Foster, Rebekah
    Winfree, Katherine B.
    Gossai, Anala
    Cui, Zhanglin Lin
    Torres, Aracelis Z.
    Feuchtbaum, Dana
    Tawney, Mahesh K.
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study
    Jiang, Haohua
    Li, Yujing
    Wang, Yanan
    Zou, Benkun
    Chen, Ya
    Zhang, Yanwei
    Husain, Hatim
    Forest, Fabien
    Qian, Fangfei
    Zhang, Lele
    Zhou, Chao
    Liu, Hongyu
    Wang, Danni
    Zhang, Wei
    Lu, Jun
    Han, Baohui
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (07)
  • [23] Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy
    Schwartzberg, Lee
    Korytowsky, Beata
    Penrod, John R.
    Zhang, Ying
    Le, T. Kim
    Batenchuk, Cory
    Krug, Lee
    CLINICAL LUNG CANCER, 2019, 20 (04) : 287 - +
  • [24] Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)
    Gadgeel, S. M.
    Zhang, Q.
    Lin, H.
    Fajardo, O.
    Trinh, H.
    Arndorfer, S.
    Kong, S.
    Rahman, A.
    Li, S.
    Archer, V. R.
    Gainor, J. F.
    ANNALS OF ONCOLOGY, 2023, 34
  • [25] Immune checkpoint inhibitors in advanced non-small cell lung cancer
    Fabre, Elizabeth
    Pecuchet, Nicola
    Cadranel, Jacques
    BULLETIN DU CANCER, 2016, 103 : S138 - S143
  • [26] Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer
    Wang, Chengdi
    Qiao, Wenliang
    Jiang, Yuting
    Zhu, Min
    Shao, Jun
    Ren, Pengwei
    Liu, Dan
    Li, Weimin
    CANCER MEDICINE, 2019, 8 (08): : 4023 - 4031
  • [27] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    CANCER, 2018, 124 (02) : 248 - 261
  • [28] Adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A single center, real-world study in China.
    Xu, Chongrui
    Tu, Hai-Yan
    Sun, Yueli
    Li, Yang-Si
    Xu, Bingfei
    Wang, Binchao
    Chen, Hua-Jun
    Wang, Zhen
    Zhou, Qing
    Yang, Jinji
    Yang, Qi
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).
    Gutierrez, Martin
    Molife, Cliff
    Belli, Andrew J.
    Hansen, Eric
    Stefaniak, Victoria Jennifer
    Winfree, Katherine B.
    Cui, Zhanglin Lin
    Batus, Marta
    Clarke, Jeffrey Melson
    Narayanan, Viraj
    Manion, Chelsea
    Norden, Andrew David
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Hyperprogressive Disease in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Lo Russo, G.
    Signorelli, D.
    Proto, C.
    Galli, G.
    Prelaj, A.
    Ferrara, R.
    Sommariva, M.
    Moro, M.
    Cancila, V.
    Ganzinelli, M.
    Brich, S.
    Sangaletti, S.
    Pruneri, G.
    Tripodo, C.
    Colombo, M. P.
    Rivoltini, L.
    Balsari, A.
    Sozzi, G.
    Boeri, M.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S245 - S245
12345